Articles citing this paper

Dr Rosemary Harrison is a Biotechnology executive with nearly 20 years of global experience working on pharmaceutical corporate strategy, portfolio management and business development. She is currently Chief Business and Strategy Officer at TCR2 Therapeutics (NASDAQ: TCRR) in Boston, USA, responsible for driving a range of activities including strategy, operational planning, corporate partnerships and long-term growth opportunities. Dr Harrison holds a Bachelor of Biotechnology in Drug Design and Development (Hons, UQ Medal) and a PhD from The University of Queensland.

Emeritus Professor Ross Barnard, FASM, was director of the biotechnology program at the University of Queensland from 2000 to 2019. Prior to that he was at Panbio Ltd (as program leader for nucleic acid diagnostics development) and the Cooperative Research Centre for Diagnostic Technologies. He has worked on diagnostics development for a variety of infectious agents. In 2005, he undertook a sabbatical at the Australian Animal Health Laboratory in Geelong, Vic., Australia (now the Australian Centre for Disease Preparedness), during which time he collaborated on the development of a broad-spectrum, RT-PCR-based Influenza A diagnostic. He was a NHMRC C. J. Martin Fellow at the University of Queensland and the University of California, Santa Cruz.

Dr Lisette Pregelj is a Lecturer in Biotechnology at The University of Queensland (UQ). Her research and teaching focuses on commercialisation of biotechnology and pharmaceutical innovations, specifically precision medicines and medical devices and the effect of regulation and innovation capabilities on their speed from discovery through to market. She previously held Postdoctoral Research Fellowships with UQ’s Business School and Australian Institute of Business and Economics.